Drug resistance and BCR‐ABL kinase domain mutations in Philadelphia chromosome–positive acute lymphoblastic leukemia from the imatinib to the second‐generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0142|120|7|1002-1009

ISSN： 0008-543x

Source： CANCER, Vol.120, Iss.7, 2014-04, pp. : 1002-1009

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

BCR/ABL1 Kinase Domain Mutation Monitoring: Could Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Benefit As Well?

By  

Acta Haematologica, Vol. 134, Iss. 2, 2015-04 ,pp. : 69-70

Karger

Access to resources Recommend Favorite

Additional Chromosome Abnormalities, BCR-ABL Tyrosine Kinase Domain Mutations and Clinical Outcome in Hungarian Tyrosine Kinase Inhibitor-Resistant Chronic Myelogenous Leukemia Patients

By  

Acta Haematologica, Vol. 127, Iss. 1, 2011-10 ,pp. : 34-42

Karger

Access to resources Recommend Favorite

Emerging BCR/ABL1 Mutations Under Treatment with Tyrosine Kinase Inhibitors in Paediatric Acute Lymphoblastic Leukaemia

By  

Acta Haematologica, Vol. 134, Iss. 2, 2015-04 ,pp. : 71-75

Karger

Access to resources Recommend Favorite

Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome‐positive acute lymphoblastic leukemia

By  

CANCER, Vol. 120, Iss. 10, 2014-05 ,pp. : 1514-1519

John Wiley & Sons Inc

Access to resources Recommend Favorite

Second-Generation Tyrosine Kinase Inhibitors in the Post-Transplant Period in Patients with Chronic Myeloid Leukemia or Philadelphia-Positive Acute Lymphoblastic Leukemia

By  

Acta Haematologica, Vol. 122, Iss. 1, 2009-07 ,pp. : 6-10

Karger

Access to resources Recommend Favorite